Skip to Content

Horizon Europe funding supports advancement of Herantis Pharma’s HER-096 in Parkinson’s disease

Herantis Pharma’s clinical-stage drug candidate HER-096 will be advanced through HERMOD, a Horizon Europe project that has secured €8 million in to support the multinational Phase 2 clinical study of HER-096, its lead candidate for the treatment of Parkinson's disease. Spinverse supported the project consortium in their successful proposal preparation process. 

HERMOD, short for HER-096 Motor Outcome and Disease Modification in Parkinson’s Disease, will evaluate the efficacy, safety and tolerability of HER-096 while also exploring innovative digital biomarkers that may help detect treatment effects and disease progression more sensitively, in people newly  diagnosed with Parkinson’s disease. The study will include a 36-week double-blind, placebo-controlled period followed by a 24-week period during which all participants will receive active treatment.

The project is coordinated by Karolinska University Hospital, while Herantis Pharma Plc, the developer of HER-096, serves as the Sponsor of the Phase 2 clinical study and leads the project’s scientific and technical implementation. Luxembourg Institute of Health leads clinical study activities in collaboration with Centre Hospitalier de Luxembourg. Karolinska University Hospital and Skåne University Hospital serve as clinical sites, and Karolinska Institutet contributes expertise in advanced brain imaging.  Originally initiated by Herantis, HERMOD builds on the company’s long-term work to develop HER-096 as a potential disease-modifying treatment for Parkinson’s disease.

The project combines clinical evaluation with digital monitoring, biomarker analyses and imaging to assess treatment effects and disease progression.

Spinverse supported Herantis Pharma in securing Horizon Europe funding

Spinverse supported Herantis Pharma in the preparation of the Horizon Europe proposal for HERMOD and helped shape the project into a strong candidate for EU funding.

Having followed the progress of Herantis Pharma in advancing HER-096 as a clinical-stage asset, Spinverse recognised Horizon Europe as a strong strategic fit for the company’s next development phase. Spinverse supported the proposal work by contributing to the project framing, proposal development and overall positioning of the funding application.

This support helped translate Herantis Pharma’s scientific and clinical ambition into a competitive Horizon Europe project with a clear focus on excellence, impact and implementation.

Spinverse’s health team worked closely with CEO Antti Vuolanto and Senior Scientist and HERMOD Technical Coordinator Ausra Domanska from Herantis Pharma during the proposal preparation process. 

Antti Vuolanto reflects on the collaboration as follows: 

Preparing a successful Horizon Europe proposal requires strong collaboration and complementary expertise. We greatly appreciated the professionalism and commitment of Spinverse throughout the HERMOD proposal preparation. Their support contributed to a successful application, and we now look forward to delivering the HERMOD project together with our consortium partners.

Ausra Domanska adds: 

Spinverse provided valuable guidance throughout the proposal preparation process, helping us navigate the Horizon Europe requirements and present our scientific and clinical development plans in a clear and structured way. Their expertise and collaborative approach made the preparation process more efficient and helped us build a strong proposal together with our consortium partners.

Toward new treatment options in Parkinson’s disease

HERMOD is intended to generate efficacy, safety and mechanistic data for HER-096 and to also support the development of more advanced approaches for assessment in Parkinson’s disease.

For Herantis Pharma, the project is an important step in advancing HER-096 in clinical development. For Spinverse, it is a strong example of how strategic proposal support can help innovative health companies secure competitive funding and move promising therapies closer to patients. 

Strong consortium across Europe

The consortium includes:

  • Herantis Pharma Plc (Finland) – Sponsor of the Phase 2 clinical study and Developer of HER-096
  • Karolinska University Hospital (Sweden) – Project Coordinator and Clinical site
  • Luxembourg Institute of Health (Luxembourg) – Clinical study lead in collaboration with Centre Hospitalier de Luxembourg, which serves as a clinical site
  • Skåne University Hospital (Sweden) – Clinical site
  • Karolinska Institutet – Centre for Imaging Research, Brain Molecular Imaging Center and MRI Center

Are you planning to accelerate your health technology innovation with Horizon Europe's Health Cluster funding? The next calls are closing on 17 February 2027 - get in touch with our funding experts today! 

Rohit Sood

Senior Director, Health Technologies, 
Ph.D. MBA, Adjunct Prof. (Medicinal Biochem.)

  rohit.sood@spinverse.com
  +358 50 530 28639


Alleima has been awarded €17.4 million in EU Innovation Fund support for next-generation clean energy technology